| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 188 | 208 | 190 | 189 | 192 | 237 | 213 | 215 | 251 | 267 | 259 | 223 | 275 | 286 | 270 | 243 | 289 | 327 | 308 | 277 | 350 | 360 | 333 | 309 | 395 | 461 | 420 | 398 | 461 | 504 | 488 | 562 | 717 | 744 | 726 | 711 | 775 | 793 |
| Expenses | 109 | 125 | 112 | 135 | 114 | 152 | 128 | 141 | 162 | 164 | 159 | 153 | 170 | 175 | 190 | 171 | 189 | 205 | 203 | 184 | 223 | 220 | 210 | 209 | 269 | 309 | 286 | 284 | 297 | 324 | 311 | 403 | 470 | 477 | 477 | 453 | 496 | 504 |
| EBITDA | 79 | 83 | 78 | 54 | 78 | 86 | 85 | 75 | 88 | 103 | 100 | 70 | 105 | 111 | 81 | 72 | 100 | 122 | 105 | 93 | 127 | 141 | 123 | 100 | 125 | 151 | 134 | 114 | 164 | 180 | 177 | 160 | 248 | 267 | 249 | 258 | 279 | 289 |
| Operating Profit % | 40 % | 37 % | 39 % | 27 % | 39 % | 34 % | 38 % | 32 % | 34 % | 37 % | 36 % | 28 % | 38 % | 38 % | 28 % | 30 % | 34 % | 37 % | 33 % | 33 % | 35 % | 38 % | 36 % | 31 % | 31 % | 32 % | 32 % | 28 % | 35 % | 35 % | 36 % | 26 % | 34 % | 35 % | 34 % | 36 % | 36 % | 36 % |
| Depreciation | 5 | 5 | 6 | 7 | 5 | 5 | 7 | 9 | 7 | 8 | 10 | 11 | 12 | 12 | 13 | 14 | 10 | 11 | 11 | 12 | 15 | 15 | 17 | 18 | 23 | 29 | 30 | 35 | 41 | 42 | 46 | 54 | 76 | 81 | 81 | 77 | 71 | 69 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 8 | 7 | 6 | 5 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 3 | 9 | 17 | 16 | 18 | 33 | 60 | 60 | 57 | 54 | 49 | 50 |
| Profit Before Tax | 73 | 78 | 72 | 48 | 74 | 99 | 77 | 62 | 78 | 92 | 89 | 58 | 95 | 103 | 72 | 62 | 95 | 116 | 99 | 85 | 117 | 131 | 109 | 85 | 101 | 121 | 107 | 76 | 113 | 126 | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 |
| Tax | 11 | 8 | 4 | 1 | 3 | 6 | 3 | 6 | 6 | 7 | 9 | 4 | 11 | 10 | 9 | 5 | 6 | 8 | 9 | 17 | 10 | 12 | 8 | 5 | 8 | 2 | 6 | 14 | 19 | 4 | 14 | -3 | 26 | 33 | 29 | 27 | 36 | 38 |
| Net Profit | 63 | 69 | 68 | 47 | 71 | 93 | 75 | 56 | 72 | 86 | 80 | 54 | 84 | 93 | 64 | 56 | 89 | 108 | 90 | 68 | 107 | 118 | 101 | 80 | 93 | 119 | 100 | 62 | 94 | 122 | 102 | 80 | 90 | 96 | 87 | 102 | 125 | 135 |
| EPS in ₹ | 45.64 | 5.02 | 4.95 | 3.43 | 5.15 | 6.75 | 5.43 | 4.06 | 5.18 | 6.20 | 5.83 | 3.93 | 6.11 | 6.74 | 4.62 | 4.13 | 6.56 | 7.93 | 6.64 | 5.03 | 7.86 | 8.71 | 7.41 | 5.91 | 6.96 | 8.84 | 7.49 | 4.81 | 6.97 | 9.08 | 7.55 | 5.22 | 6.11 | 6.73 | 6.16 | 6.90 | 8.66 | 8.82 |
Eris Lifesciences
Eris Lifesciences
1,652.10
-31.90
(-1.89%)
There are 4 new updates from the company20 hours ago
View
Key Fundamentals
Market Cap
22,503.84 Cr
EPS
25.85
PE Ratio
50.71
Dividend Yield
0.44 %
Industry
Healthcare 52 Week High
1,910.00
52 Week Low
1,097.20
PB Ratio
7.37
Debt to Equity
0.97
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from10 analysts
Actual
Company News
View All News
Eris Lifesciences purchased a 30% stake in its subsidiary Swiss Parenterals Ltd for ₹4.23 billion. The acquisition strengthens the pharmaceutical company's ownership position in the unit through this significant investment.
Eris Lifesciences Board to Consider Preferential Share Issue for Swiss Parenterals Acquisition
6 days ago
6 days agoEris Lifesciences has scheduled a board meeting for November 24, 2025, to consider issuing equity shares through preferential allotment for acquiring the remaining 30% stake in Swiss Parenterals Limited. The company will also consider convening an extraordinary general meeting to seek shareholder approval for the proposed preferential issue.
Eris Lifesciences Allots 3,337 Equity Shares Under ESOP Scheme7 days ago
Eris Lifesciences allotted 3,337 equity shares on November 17, 2025, under its ESOP-2021 scheme with 983 shares from 2023 grants at Rs. 510.32 per share and 2,354 shares from 2024 grants at Rs. 728.16 per share. The company's paid-up share capital increased from Rs. 13,62,13,554 to Rs. 13,62,16,891, reflecting the addition of new equity shares for employee stock option exercises.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,776.80 | #1 4,26,313.84 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 70.04 | |
6,412.00 | 1,70,218.45 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 45.55 | |
3,745.20 | 1,26,754.59 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 56.93 | |
1,507.50 | 1,21,768.93 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 42.68 | |
1,236.10 | 1,03,166.61 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 48.69 | |
928.50 | 93,428.83 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 34.91 | |
2,042.30 | 93,282.98 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 59.01 | |
2,241.90 | 92,536.33 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 35.90 | |
1,208.00 | 70,160.84 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 61.70 | |
5,701.00 | 68,164.01 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 57.85 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
43.24 %
Net Income Growth
-5.64 %
Cash Flow Change
119.13 %
ROE
-7.06 %
ROCE
11.27 %
EBITDA Margin (Avg.)
3.46 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,041 | 7,033 |
| Fixed Assets | 65 | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,307 |
| Current Assets | 237 | 216 | 299 | 582 | 480 | 467 | 627 | 765 | 2,302 | 1,223 |
| Capital Work in Progress | 0 | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 |
| Investments | 144 | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 |
| Other Assets | 190 | 192 | 324 | 435 | 595 | 685 | 807 | 1,041 | 2,686 | 1,593 |
| Total Liabilities | 398 | 727 | 1,460 | 1,554 | 1,552 | 1,835 | 2,272 | 3,667 | 7,041 | 7,033 |
| Current Liabilities | 71 | 76 | 226 | 306 | 165 | 167 | 200 | 443 | 2,532 | 1,381 |
| Non Current Liabilities | 25 | 60 | 349 | 79 | 91 | 91 | 164 | 1,003 | 1,286 | 2,380 |
| Total Equity | 302 | 591 | 886 | 1,169 | 1,296 | 1,576 | 1,908 | 2,221 | 3,222 | 3,272 |
| Reserve & Surplus | 302 | 553 | 848 | 1,137 | 1,283 | 1,563 | 1,894 | 2,182 | 2,573 | 2,841 |
| Share Capital | 0 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 4 | -8 | 8 | -3 | 60 | -30 | 14 | 5 | 38 | 106 |
| Investing Activities | -92 | -44 | -185 | -590 | -5 | 123 | -323 | -320 | -975 | -1,828 | -78 |
| Operating Activities | 90 | 132 | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 |
| Financing Activities | 1 | -84 | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 |
Share Holding
| % Holding | Jan 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 55.55 % | 54.13 % | 52.69 % | 52.68 % | 52.66 % | 52.66 % | 52.30 % | 52.29 % | 52.70 % | 52.86 % | 52.86 % | 54.91 % | 54.90 % | 54.90 % | 54.88 % | 54.87 % | 54.86 % | 54.85 % | 54.83 % | 54.85 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 13.20 % | 0.00 % | 14.27 % | 14.59 % | 8.01 % | 8.35 % | 8.43 % | 8.40 % | 7.21 % |
| DIIs | 10.52 % | 9.25 % | 9.66 % | 9.57 % | 9.99 % | 10.11 % | 10.36 % | 10.38 % | 9.94 % | 10.02 % | 10.28 % | 14.53 % | 13.86 % | 15.63 % | 16.23 % | 18.64 % | 18.06 % | 18.07 % | 18.17 % | 19.36 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 22.42 % | 23.28 % | 23.23 % | 23.29 % | 23.19 % | 23.14 % | 21.34 % | 21.27 % | 21.45 % | 21.66 % | 22.07 % | 15.47 % | 15.67 % | 14.24 % | 13.53 % | 10.51 % | 9.29 % | 9.16 % | 9.12 % | 9.12 % |
| Others | 11.51 % | 13.34 % | 14.42 % | 14.46 % | 14.16 % | 14.09 % | 16.01 % | 16.07 % | 15.90 % | 15.46 % | 14.79 % | 1.90 % | 15.57 % | 0.95 % | 0.77 % | 7.96 % | 9.43 % | 9.49 % | 9.47 % | 9.45 % |
| No of Share Holders | 29,195 | 41,470 | 46,477 | 49,833 | 54,223 | 57,061 | 51,639 | 48,055 | 46,746 | 45,931 | 44,169 | 42,245 | 46,496 | 51,753 | 44,176 | 46,346 | 53,314 | 50,087 | 52,225 | 59,438 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 2.87 | 5.5 | 6.01 | 7.35 | 0.00 | 7.35 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.47 | 0.8 | 1.05 | 0.87 | 0.00 | 0.44 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 06 Aug 2021 |  Dividend | ₹ 6.01 /share | 05 Aug 2021 | 742.15 | 747.90 |
| 16 Aug 2022 | Dividend | ₹ 7.35 /share | 11 Aug 2022 | 696.65 | 695.05 |
| 25 Sept 2024 |  Annual General Meeting | NA | 25 Sept 2024 | 1,454.10 | 1,311.75 |
| 25 Oct 2024 |  Quarterly Result Announcement | NA | 25 Oct 2024 | 1,329.15 | 1,282.30 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,157.90 | 1,248.00 |
| 13 Feb 2025 | Dividend | ₹ 7.35 /share | 13 Feb 2025 | 1,460.10 | 1,301.85 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 1,402.05 | 1,465.15 |
| 25 Jul 2025 | Annual General Meeting | NA | 25 Jul 2025 | 1,679.60 | 1,780.65 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 1,791.20 | 1,801.10 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 1,599.60 | 1,595.20 |
Announcements
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot20 hours ago
20 hours agoAnnouncement under Regulation 30 (LODR)-Acquisition23 hours ago
23 hours agoAnnouncement under Regulation 30 (LODR)-Issue of Securities23 hours ago
23 hours agoBoard Meeting Outcome for Meeting Dated November 24 202523 hours ago
23 hours agoBoard Meeting Intimation for Issuance Of Equity Shares Of The Company By Way Of A Preferential Issue6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2025
Nov 12, 2025Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 12, 2025
Nov 12, 2025Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 06, 2025
Nov 06, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 06, 2025
Nov 06, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 25, 2025
Aug 25, 2025Announcement Under Regulation 30 (LODR) - Receipt Of Show Cause NoticeAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Resignation of Statutory AuditorsAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 05, 2025
Aug 05, 2025Unaudited Financial Results For The Quarter Ended June 30 2025Aug 05, 2025
Aug 05, 2025Board Meeting Outcome for The Board Meeting Held On August 05 2025Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 31, 2025
Jul 31, 2025Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended June 30 2025Jul 30, 2025
Jul 30, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 28, 2025
Jul 28, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 21, 2025
Jul 21, 2025Update To The Notice Convening The 19Th Annual General MeetingJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Jul 03, 2025Book Closure For Annual General MeetingJul 02, 2025
Jul 02, 2025Shareholders Meeting - Annual General Meeting - July 25 2025Jul 02, 2025
Jul 02, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 02, 2025
Jul 02, 2025Reg. 34 (1) Annual Report.Jul 02, 2025
Jul 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Jul 02, 2025Board Meeting Outcome for The Meeting Held On June 30 2025Jun 30, 2025
Jun 30, 2025Board Meeting Outcome for The Meeting Held On June 30 2025Jun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Corporate PresentationJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 11, 2025
Jun 11, 2025Mutual Fund Holdings
Franklin India Opportunities Direct Fund-Growth 
HDFC Small Cap Fund Direct- Growth 
HSBC Small Cap Fund Direct-Growth 
Mirae Asset Healthcare Fund Direct - Growth 
UTI Flexi Cap Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty500 Momentum 50 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth 
SBI Nifty 500 Index Fund Direct-Growth 
Bandhan Nifty 500 Momentum 50 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 65.14
ATR(14)
Volatile 45.88
STOCH(9,6)
Neutral 75.90
STOCH RSI(14)
Overbought 99.17
MACD(12,26)
Bullish 13.68
ADX(14)
Weak Trend 16.36
UO(9)
Bearish 73.34
ROC(12)
Uptrend And Accelerating 6.22
WillR(14)
Overbought -7.01
About Eris Lifesciences
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands and a distribution network of 22 sales depots, 2,059 stockists, and over 500,000 retail chemists. Eris has expanded through acquisitions and launches of new divisions. It has five wholly-owned subsidiaries and has acquired various brands and businesses in recent years, including dermatology and cosmetology brands. The company also produces human insulin and has entered the anti-thrombotics segment.
Listing Date
29 Jun, 2017(8 Years,
-4 days)
Website
Chairperson NameAmit Indubhushan Bakshi
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
